-
-
-
-
-
-
-
BTIG Reiterates Buy Rating on Verastem (VSTM)
-
-
-
-
-
-
-
Verastem Oncology (VSTM) Tops Q2 EPS by 12c
-
-
-
-
-
-
-
Verastem (VSTM) PT Lowered to $18 at BTIG
-
-
-
-
-
-
-
Jefferies Reiterates Buy Rating on Verastem (VSTM); "catalyst-rich 2026"
-
-
-
-
-
-
-
Verastem (VSTM) PT Raised to $14 at RBC Capital; 'Stock Is Oversold'
-
-
-
-
-
-
-
Verastem (VSTM) PT Lowered to $14 at Mizuho
-
-
-
-
-
-
-
Verastem Oncology (VSTM) announces publication of results from Phase 1 FRAME study
-
483,138 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All


